Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Mucormycosis (previously called as zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses. The fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma. Mucormycosis needs to be treated with prescribed antifungal medication such as amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally.
India Mucormycosis Treatment (Black Fungus Drugs) Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period, owing to increasing cases of mucormycosis infection in the COVID-19 positive or in patients who have recovered from COVID-19 infection. For instance, according to the article published in the Diabetes and Metabolic Syndrome Journal: May 21, 2021, COVID-19 infection has been associated with a wide range of bacterial and fungal infections. Currently, mucormycosis infection cases are rising in the Indian population due to the presence of ideal environment in the COVID-19 patients, low oxygen, high glucose (in case of diabetes or steroid induces hyperglycemia), acidic medium (diabetic ketoacidosis and others), high iron levels, and suppressed immune system along with other comorbidities.
|To control hyperglycemia
||Do not miss warning signs and symptoms
|To monitor blood glucose level post COVID-19 discharge and also in diabetics
||Do not ignore and consider that the cases with blocked nose as cases of bacterial sinusitis, particularly in patients with immunosuppression and/or COVID-19 patients on immunomodulators
|To use steroid properly
||Do not self-medicate and seek investigations (KOH staining & microscopy, culture, MALDITOF) for detecting fungal infection
|To use clean, sterile water for humidifiers during oxygen therapy
||Do not lose crucial time to initiate treatment for mucormycosis
|To use antibiotics/antifungals with care
Government authorities are spreading awareness for the early detection and management of mucormycosis in the COVID-19 patients. For instance, Indian Council of Medical Research (ICMR), released guidelines i.e., Dos and Don’ts for the COVID – 19 patients.
India Mucormycosis Treatment (Black Fungus Drugs) Market Report Coverage
||Market Size in 2021:
||US$ 9.1 Mn
|Historical Data for:
||2018 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2027 Value Projection:
||US$ 11.7 Mn
- By Drugs: Amphotericin B, Isavuconazole, Posaconazole, Voriconazole, Flucytosine, Fluconazole, Others
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums and Vaccines, BDR Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited, and TLC Pharma Labs
- Increasing collaboration among the market players
- Increasing prevalence of mucormycosis
- Increasing allotment of license to the manufacturers for production of Amphotericin B
- Increasing government initiatives for increasing availability of drugs for the treatment of mucormycosis
|Restraints & Challenges:
- High cost of the treatment of mucormycosis
- Drug shortages
India Mucormycosis Treatment (Black Fungus Drugs) market is estimated to be valued at US$ 9.1 Mn in 2021 and is expected to exhibit a CAGR of 3.5% over the forecast period (2021-2028).
Figure 1: India Mucormycosis Treatment (Black Fungus Drugs) Market Share (%) Analysis, By Species, 2021
Market Players are engaged in receiving license from the Indian government, in order to manufacture Amphotericin – B, an anti-fungal drug for the treatment of Black Fungus or mucormycosis. This is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.
Indian government has provided license to some of the market players, in order to manufacture anti-fungal drug, Amphotericin – B for the treatment of Mucormycosis (Black Fungus Drugs). For instance, on May 22, 2021, Indian government gave license to five manufacturers: Emcure Pharmaceuticals, Natco Pharmaceuticals, Gufic Biosciences, Alembic Pharmaceuticals, and Lyca Pharmaceuticals. These companies will start producing 111,000 vials of Amphotericin – B each month from July 2021.
Key players are engaged in entering into an agreement, in order to manufacture anti- fungal drugs for black fungus. This is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.
The increasing agreements by the market players for the manufacture of anti-fungal drug in the treatment of mucormycosis is expected to drive growth of the market over the forecast period. For instance, on May 26, 2021, Cadila Healthcare Limited and TLC Pharma Labs, entered into an agreement to manufacture anti-fungal drug ‘Liposomal Amphotericin B’ for the treatment of mucormycosis or black fungus in India.
Increasing prevalence of mucormycosis in the Indian population with comorbidities is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market
In India, diabetes mellitus is the most common underlying disease. For instance, according to the article published in the Microorganism Journal, on March 4, 2021, the pie chart shows the percentage of mucormycosis burden in different at-risk populations in India. According to the same source, diabetes mellitus is a common predisposing factor for the rhino-orbital-cerebral mucormycosis (ROCM) type of disease. A recent study from India reported that 77% of ROCM cases were in the diabetic population.
Moreover, according to the article published by the Indian Ministry of Chemicals and Fertilizers, around 8,848 cases of mucormycosis has been reported till May 25, 2021 in India. The following graph shows the number of cases of mucormycosis infection reported in each state in India, till May 25, 2021.
India Mucormycosis Treatment (Black Fungus Drugs) Market – Restraints
High cost of the medicines for the treatment of mucormycosis is expected to restrain growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period. For instance, the only antifungal drug, Amphotericin B is expensive and it will be difficult for the people to bear the cost. Currently the single vial of the drug is available in the market at a price of US$ 68.6 to US$ 109.9 (5,000 to 8,000 Indian rupees). Moreover the medicines have to be taken for 4 to 12 weeks, thus, many patients fail to take the treatment due to high cost. Government intervention may help in curbing the cost of the medicines.
Furthermore, drug shortages is another factor, which may hamper growth of the market. For instance, Kerala, a state in South India, declared Amphotericin B shortage in the market. Moreover, on an average a mucormycosis patient requires 100 vials of Amphotericin B for their treatment. Thus, India will require 9 to 10 lakhs injections of Amphotericin B for 9,000 mucormycosis patients. Thus, the above factors are expected to restrain the growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.
Figure 2: India Mucormycosis Treatment (Black Fungus Drugs) Market Value (US$ Mn) & Y-o-Y Growth (%), 2020 - 2028
India Mucormycosis Treatment (Black Fungus Drugs) Market – Competitive Landscape
Major players operating in the India Mucormycosis Treatment (Black Fungus Drugs) market include Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums and Vaccines, BDR Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited, and TLC Pharma Labs